These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37144597)

  • 41. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
    Landau SM; Horng A; Fero A; Jagust WJ;
    Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved.
    Hanseeuw B; Dricot L; Lhommel R; Quenon L; Ivanoiu A
    J Alzheimers Dis; 2016 May; 53(2):651-60. PubMed ID: 27232217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer's disease to Parkinson's disease.
    Choi H; Kim YK; Yoon EJ; Lee JY; Lee DS;
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):403-412. PubMed ID: 31768599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic Moderation of the Association of β-Amyloid With Cognition and MRI Brain Structure in Alzheimer Disease.
    Insel PS; Kumar A; Hansson O; Mattsson-Carlgren N;
    Neurology; 2023 Jul; 101(1):e20-e29. PubMed ID: 37085326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic utility and characteristics of CT-based attenuation correction in brain perfusion SPECT/CT in predicting the exacerbation of Alzheimer changes from mild cognitive impairment utilizing voxel-based statistical analysis in comparison with Chang's method.
    Sohara K; Kiriyama T; Mizumura S; Ishiwata A; Yamazaki M; Kimura K; Kumita SI
    Ann Nucl Med; 2020 Jul; 34(7):502-511. PubMed ID: 32449110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive Impairment.
    Seo EH; Kim SH; Park SH; Kang SH; Choo IH;
    J Korean Med Sci; 2016 Feb; 31(2):286-95. PubMed ID: 26839485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy.
    Chai L; Luo Q; Cai K; Wang K; Xu B
    BMC Nephrol; 2021 Jun; 22(1):209. PubMed ID: 34082732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation and comparison of short chain fatty acids composition in gut diseases.
    Niccolai E; Baldi S; Ricci F; Russo E; Nannini G; Menicatti M; Poli G; Taddei A; Bartolucci G; Calabrò AS; Stingo FC; Amedei A
    World J Gastroenterol; 2019 Sep; 25(36):5543-5558. PubMed ID: 31576099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
    Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
    J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Correlation of muscle strength with cognitive function and medial temporal lobe atrophy in patients with mild to moderate Alzheimer's disease].
    Liu SW; Li M; Zhu JT; Zhang YC; Wu YH; Liu CF; Hu H
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(35):2786-2792. PubMed ID: 36124351
    [No Abstract]   [Full Text] [Related]  

  • 54. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
    Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
    EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
    Landau SM; Lu M; Joshi AD; Pontecorvo M; Mintun MA; Trojanowski JQ; Shaw LM; Jagust WJ;
    Ann Neurol; 2013 Dec; 74(6):826-36. PubMed ID: 23536396
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment.
    Nagpal R; Neth BJ; Wang S; Craft S; Yadav H
    EBioMedicine; 2019 Sep; 47():529-542. PubMed ID: 31477562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.